Irofulven CAS:920014-72-8

Irofulven is primarily utilized in oncology for its cytotoxic effects and potential therapeutic benefits: Anticancer Activity: Irofulven induces apoptosis in cancer cells by damaging their DNA, making it effective against tumors that have developed resistance to other treatments. Solid Tumor Treatment: It has been studied for the treatment of solid tumors such as prostate, bladder, and ovarian cancers, where it has shown activity even in advanced stages of the disease. Combination Therapy: Researchers explore Irofulven in combination with other chemotherapy agents or radiation therapy to enhance treatment outcomes and reduce resistance. Clinical Trials: Ongoing clinical trials assess its efficacy, safety, and potential side effects in diverse patient populations, aiming to establish its role in cancer treatment protocols. Mechanism of Action: Understanding its unique mechanism of action helps in developing targeted therapies and improving treatment strategies for difficult-to-treat cancers. Irofulven's development highlights its potential as a valuable addition to oncology treatments, offering hope for patients with aggressive cancers that are resistant to standard therapies.